Last reviewed · How we verify

NCT06687187: Gastric

Effect of Two Different Doses of Neostigmine on the Gastric Residual Volume and Aspiration in Critically Ill Patients

Completed Last updated 13 November 2024
What this trial tests

trial testing Neostigmine in Gastric Reflux in 3 participants. Completed in 1 May 2024.

Timeline
1 December 2022
Primary endpoint
1 April 2024
1 May 2024

Quick facts

Lead sponsorZulekha Hospitals
StatusCompleted
Study typeOBSERVATIONAL
Enrollment3
Start date1 December 2022
Primary completion1 April 2024
Estimated completion1 May 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Zulekha Hospitals

Who can join

Adults 20 to 60, any sex, with Gastric Reflux. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study comparing the effect of two doses of neostigmine on the gastric residual volume in critically ill patients on enteral feeding.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effect of Two Different Doses of Neostigmine on the Gastric Residual Volume and Aspiration in Critically Ill Patients Under Enteral Feeding; A Comparative Controlled Randomized Trial.
    Seyam SHA, Elabd Hassan I, Elabd Hassan A, Mohamad Elsayed M. · · 2025 · PMID 40452960 · DOI 10.5812/aapm-158019

Verify or expand the search:

Other trials of Neostigmine

Trials testing the same drug.

Other recruiting trials for Gastric Reflux

Currently open trials in the same condition.

Other Zulekha Hospitals trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06687187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing